NMRA Q2 2023 Earnings — Neumora Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

NMRANeumora Therapeutics, Inc. Common Stock

$586M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$42M

Net Income

-$39M

EPS (Diluted)

$-0.25

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$360M

Total Liabilities

$873M

Stockholders' Equity

-$514M

Cash & Equivalents

$204M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$42M	-$31M	-34.3%
Net Income	-$39M	-$30M	-26.9%